Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
114 hedge funds and large institutions have $1.79B invested in Soleno Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 45 increasing their positions, 25 reducing their positions, and 17 closing their positions.
106% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 17
80% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 25
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
18% more capital invested
Capital invested by funds: $1.52B → $1.79B (+$271M)
16% more funds holding
Funds holding: 98 → 114 (+16)
11% more ownership
Funds ownership: 109.48% → 120.48% (+11%)
87% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $15.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$65.1M |
| 2 |
CC
Commodore Capital
New York
|
+$53.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$38.6M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$30.9M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$28.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$46.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$13.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$7.54M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.08M |
| 5 |
SC
Stempoint Capital
New York
|
-$4.96M |
SLNO Hedge Fund Activity: Q2 2024 in Review
114 of the 6,931 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2024, worth a combined $1.79B — up 18% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new SLNO positions and 17 closed out — a net gain of 18 holders — while 45 added to existing stakes and 25 trimmed.
The largest buyer was BlackRock, adding an estimated $65.1M. The largest seller was Vivo Capital, cutting an estimated $46.7M.
- 114 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2024, up from 98 in Q1 2024.
- Funds reported $1.79B of Soleno Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
- 35 funds opened new Soleno Therapeutics positions in Q2 2024 and 17 closed out, a net change of +18 holders.
- The largest Soleno Therapeutics buyer in Q2 2024 was BlackRock, an estimated $65.1M added.
- The largest Soleno Therapeutics seller in Q2 2024 was Vivo Capital, an estimated $46.7M sold.
Based on aggregated 13F filings for Q2 2024.